Trial Profile
A Phase 2, Randomized, Double-Blind, Placebo and Active-Controlled Trial of LY2951742 in Patients With Mild to Moderate Osteoarthritis Pain of the Knee
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Galcanezumab (Primary) ; Celecoxib
- Indications Osteoarthritis; Pain
- Focus Therapeutic Use
- Sponsors Eli Lilly and Company
- 17 Jun 2017 Interim results presented at the 18th Annual Congress of the European League Against Rheumatism.
- 11 Jun 2017 Results (n=266) assessing the effects of galcanezumab on blood pressure, presented at the 59th Annual Scientific Meeting of the American Headache Society.
- 29 Jun 2015 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov record.